Status of novel coronavirus disease and analysis of mortality in Mexico, until June 30th, 2020: an ecological study

Introduction. Mexico has high number of new cases of Coronavirus Infectious Disease-19 and high rates of diabetes, hypertension, obesity, smoking, that can increase the mortality. The aim was to analyze the evolution of the disease until June 30th, 2020;to know the Cause-Specific Mortality Rate by each state from Mexico and the effect of co-morbidities on mortality for Coronavirus Infectious Disease-19. Methods. An ecological study was designed with public data of National Epidemiological Surveillance System to compare the hospital infrastructure (beds) and Cause-Specific Mortality Rate in each state from Mexico and analyze the effect of co-morbidities in mortality by Coronavirus Infectious Disease.19. It was used t-Student test, Z for two proportions, P-values, and OR, CI95%, and logistic regression . Results. From 509,539 registries, 226,089 (44.37%) were confirmed cases and 27,769 deaths were reported (12.28%). The states with higher mortality were Morelos, Baja California, Chihuahua, Guerrero. There was a lineal relationship between number of beds and cause-specific mortality rate (P<,05). Diabetes, chronic obstructive pulmonary disease, immunosuppression, hypertension, cardiovascular disease, chronic kidney disease and obesity shown a stronger effect on mortality by coronavirus disease (OR higher than 2). Asthma shown a protective effect on mortality from coronavirus disease in Mexican population. Conclusion. The spread on coronavirus disease is active in Mexico. The comorbidities had a stronger effect on mortality of Coronavirus disease.

Status of novel coronavirus disease and analysis of mortality in Mexico, until June 30th, 2020: An ecological study

Mexico has high number of new cases of Coronavirus Infectious Disease-19 and high rates of diabetes, hypertension, obesity, smoking, that can increase the mortality. The aim was to analyze the evolution of the disease until June 30th, 2020;to know the Cause-Specific Mortality Rate by each state from Mexico and the effect of co-morbidities on mortality for Coronavirus Infectious Disease-19. Methods. An ecological study was designed with public data of National Epidemiological Surveillance System to compare the hospital infrastructure (beds) and Cause-Specific Mortality Rate in each state from Mexico and analyze the effect of co-morbidities in mortality by Coronavirus Infectious Disease.19. It was used t-Student test, Z for two proportions, P-values, and OR, CI95%, and logistic regression.Results. From 509,539 registries, 226,089 (44.37%) were confirmed cases and 27,769 deaths were reported (12.28%). The states with higher mortality were Morelos, Baja California, Chihuahua, Guerrero. There was a lineal relationship between number of beds and cause-specific mortality rate (P<,05). Diabetes, chronic obstructive pulmonary disease, immuno suppression, hypertension, cardiovascular disease, chronic kidney disease and obesity shown a stronger effect on mortality by coronavirus disease (OR higher than 2). Asthma shown a protective effect on mortality from coronavirus disease in Mexican population. Conclusion. The spread on coronavirus disease is active in Mexico. The comorbidities had a stronger effect on mortality of Coronavirus disease. © 2020 This is an Open Access article licensed under a Creative Commons license: Attribution 4.0 International (CC-BY). Published by Oriental Scientific Publishing Company.

SARS-CoV-2 infection and coronavirus disease (COVID-19) clinical data: A review of the literature

The aim was to describe the clinical data from patients with confirmed cases of COVID-19 and clinical data of patients with pneumonia by the same virus. It was selected articles on clinical data from patients with COVID-19 and pneumonia by SARS-CoV-2 in pubmed, embase and google schoolar. It was described the clinical data of patients with COVID-19 from 3 studies with 1,078 patients. The main clinical data for COVID-19 were cough 60.4%, fever 40.9%, and production of sputum 26.0%. For pneumonia by SARS-CoV-2, was described clinical data from 495 patients from 5 studies, were fever 77.4%, cough 68.9%, and myoarthralgia 49.9%. In children with COVID-19 was reported cough 48.5%, pharyngeal erythema 46,2%, and fever 41.5%. To use only clinical data to submit patients to RT-PCR test is not good, because many infected patients have not clinical data (asymptomatic carriers) or they did not reported the main clinical data as fever, cough or myoarthralgia.